CSIMarket
 


Vor Biopharma Inc   (VOR)
Other Ticker:  
 

Vor Biopharma Inc 's Working Capital Ratio

VOR's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 14.12 a new company low.

Within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Working Capital Ratio than Vor Biopharma Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 136 to 306.

Explain Working Capital Ratio
How much in Current Assets VORīs has?
What is the value of VORīs Current Liabilities?


VOR Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 58.54 % 15.23 % -18.39 % 18.44 % -8.9 %
Y / Y Current Assets Change 15.21 % 20.49 % 13.98 % 10.52 % -38.5 %
Working Capital Ratio MRQ 14.12 21.2 24.46 24.06 19.43
VOR's Total Ranking # 306 # 136 # 152 # 173 # 281
Seq. Current Liabilities Change 29.02 % 1.8 % -9.96 % 34.06 % -6.23 %
Seq. Current Assets Change -14.08 % -11.76 % -8.46 % 66.01 % -10.14 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 126
Overall Market # 306


Working Capital Ratio Statistics
High Average Low
35.62 24.2 14.12
(Mar 31 2021)   (Sep 30 2023)




Financial Statements
Vor Biopharma Inc 's Current Liabilities $ 12 Millions Visit VOR's Balance sheet
Vor Biopharma Inc 's Current Assets $ 164 Millions Visit VOR's Balance sheet
Source of VOR's Sales Visit VOR's Sales by Geography


Cumulative Vor Biopharma Inc 's Working Capital Ratio

VOR's Working Capital Ratio for the trailling 12 Months

VOR Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 58.54 % 15.23 % -18.39 % 18.44 % -8.9 %
Y / Y Current Assets TTM Growth 15.21 % 20.49 % 13.98 % 10.52 % -38.5 %
Working Capital Ratio TTM 20.56 22.46 22.29 20.31 20.56
Total Ranking TTM # 3700 # 2558 # 77 # 45 # 181
Seq. Current Liabilities TTM Growth 29.02 % 1.8 % -9.96 % 34.06 % -6.23 %
Seq. Current Assets TTM Growth -14.08 % -11.76 % -8.46 % 66.01 % -10.14 %


On the trailing twelve months basis Due to growth in Current Liabilities in the III Quarter 2023 to $11.65 millions, cumulative Working Capital Ratio decreased to 20.56 above the VOR average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 162 other companies have achieved higher Working Capital Ratio than Vor Biopharma Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2558 to 3700.

Explain Working Capital Ratio
How much in Current Assets VORīs has?
What is the value of VORīs Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 163
Healthcare Sector # 981
Within the Market # 3700


trailing twelve months Working Capital Ratio Statistics
High Average Low
26.5 16.9 13.34
(Dec 31 2021)   (Dec 31 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Cortexyme Inc   37.80 $ 85.173  Millions$ 2.253  Millions
Acumen Pharmaceuticals Inc   35.85 $ 218.598  Millions$ 6.098  Millions
Vaxcyte Inc   34.41 $ 1,295.434  Millions$ 37.650  Millions
Creative Medical Technology Holdings Inc   29.59 $ 12.044  Millions$ 0.407  Millions
Revolution Medicines Inc   27.83 $ 824.467  Millions$ 29.627  Millions
Apogee Therapeutics inc   24.82 $ 426.421  Millions$ 17.178  Millions
Intensity Therapeutics Inc   22.98 $ 16.635  Millions$ 0.724  Millions
Cullinan Oncology Inc   21.77 $ 476.712  Millions$ 21.897  Millions
Krystal Biotech Inc   21.10 $ 582.128  Millions$ 27.583  Millions
Prokidney Corp  20.01 $ 406.423  Millions$ 20.311  Millions
Graphite Bio Inc   19.05 $ 238.783  Millions$ 12.537  Millions
Tourmaline Bio Inc   18.64 $ 151.047  Millions$ 8.105  Millions
Avrobio Inc   18.47 $ 109.170  Millions$ 5.912  Millions
Compass Therapeutics Inc   18.26 $ 166.584  Millions$ 9.124  Millions
4d Molecular Therapeutics Inc   18.07 $ 328.243  Millions$ 18.163  Millions
Icosavax Inc   18.06 $ 235.307  Millions$ 13.030  Millions
Neumora Therapeutics Inc   18.05 $ 525.735  Millions$ 29.123  Millions
Fusion Pharmaceuticals Inc   17.97 $ 203.265  Millions$ 11.312  Millions
Hillevax Inc   17.58 $ 333.195  Millions$ 18.958  Millions
Relay Therapeutics Inc   16.39 $ 831.798  Millions$ 50.748  Millions
Denali Therapeutics Inc   16.06 $ 1,142.884  Millions$ 71.180  Millions
Crispr Therapeutics Ag  15.83 $ 1,760.586  Millions$ 111.234  Millions
Cabaletta Bio Inc   15.65 $ 166.178  Millions$ 10.616  Millions
Voyager Therapeutics Inc   15.03 $ 261.925  Millions$ 17.427  Millions
Iteos Therapeutics Inc   14.28 $ 619.128  Millions$ 43.349  Millions
Caribou Biosciences Inc   14.27 $ 350.693  Millions$ 24.572  Millions
Aura Biosciences Inc   14.13 $ 153.888  Millions$ 10.894  Millions
Vor Biopharma Inc   14.12 $ 164.438  Millions$ 11.645  Millions
Pharmacyte Biotech Inc   14.08 $ 73.748  Millions$ 5.240  Millions
Vigil Neuroscience Inc   13.79 $ 139.847  Millions$ 10.142  Millions

Date modified: 2023-11-08T19:01:59+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com